Clinical Trial

Energy Metabolism and Acute Effects of Protein Diets in Metabolically Obese Normal Weight Individuals

Study acronym: MONW
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 31, 2025 (before its estimated February 2025 completion). Its status may not reflect the trial's current state.
Summary
Asians tend to develop type 2 diabetes (T2D) at lower body mass index (BMI) levels and younger ages compared to other populations. This leads to a longer duration of suffering from long-term complications associated with the disease, ultimately resulting in shorter life expectancy. Notably, approximately 40% of newly diagnosed T2D cases in Asians occur in individuals considered lean, with a BMI reported to be less than 22 kg/m2. This phenomenon is termed the "Metabolically Obese Normal Weight" (MONW) phenotype. MONW individuals are characterized as having a normal body weight but exhibiting obesity-related metabolic disturbances, including excess body fat with ectopic fat deposition, insulin resistance, and dyslipidemia.
Trial Details
NCT Number NCT06802341
Lead Sponsor Singapore Institute of Food and Biotechnology Innovation
Conditions Healthy, Glucose Metabolism Disorders, Obesity, Visceral, Obesity; Endocrine, Insulin Sensitivity, Insulin Resistance
Enrollment 24 participants
Start Date 2022-02-01
Primary Completion 2025-02 (estimated)
Study Completion 2025-02 (estimated)
Updated on ClinicalTrials.gov 2025-01-31